The Case for Understanding Biomedical Innovation Better

As pressure once again increases on domestic discretionary spending, the national debate about drug pricing and the cost of health care in general, intensifies. In addition, discussion of tax policy for repatriating billions of profits parked abroad provokes the question: Are there opportunities for using policy to reconfigure incentives for biomedical innovation that better align investments with health outcomes?

This talk features Robert Cook-Deegan, professor at Arizona State University's School for the Future of Innovation in Society.

Cook-Deegan’s areas of expertise include genomics and intellectual property, history of genomics, global health, science and health policy and health research policy.

Kimberly Quach

Consortium for Science, Policy & Outcomes

202-446-0386

kimberly.quach@asu.edu

http://cspo.org/cspo-in-dc/